4B ); however, compared with patients with non– CCNE1 -amplified gastric adenocarcinoma, patients with CCNE1 -amplified gastric adenocarcinoma showed a trend toward shorter survival after receiving trastuzumab (HR = 1.694, 95% CI: 0.873–3.289, P = 0.115; Fig. 4C ).
These differences in survival outcomes with trastuzumab or immunotherapy were limited to CCNE1 -amplified gastric adenocarcinoma, as we did not find any significant survival differences in CCNE1 -amplified EA or EJC after trastuzumab or immunotherapy, although there was a slight trend toward improved survival after immunotherapy in CCNE1 -amplified EJC ( Supplementary Fig.